1. Falchook, GS, Wolff, RA, Varadhachary, GR. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 2008; 108: 515–519.
Google Scholar | Crossref | Medline2. Moore, RG, Chung, M, Granai, CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 2004; 93: 87–91.
Google Scholar | Crossref | Medline | ISI3. Fujiwara, K, Ohishi, Y, Koike, H, et al. Clinical implications of metastases to the ovary. Gynecol Oncol 1995; 59: 124–128.
Google Scholar | Crossref | Medline4. Mazur, MT, Hsueh, S, Gersell, DJ. Metastases to the female genital tract. Analysis of 325 cases. Cancer 1984; 53: 1978–1984.
Google Scholar | Crossref | Medline | ISI5. Ulbright, TM, Roth, LM, Stehman, FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer 1984; 53: 1164–1174.
Google Scholar | Crossref | Medline6. Young, RH, Hart, WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol 1989; 13: 748–756.
Google Scholar | Crossref | Medline7. Young, RH . From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, Mucinous tumors including the Krukenberg tumor. Adv Anat Pathol 2006; 13: 205–227.
Google Scholar | Crossref | Medline8. Classic pages in obstetrics and gynecology: Friedrich Ernst Krukenberg Fibrosarcoma ovarii mucocellulare (carcinomatodes) . Archiv für Gynäkologie, vol 50, pp. 287–321, 1896. Am J Obstet Gynecol 1973; 117: 575.
Google Scholar | Medline9. Petru, E, Pickel, H, Heydarfadai, M, et al. Nongenital cancers metastatic to the ovary. Gynecol Oncol 1992; 44: 83–86.
Google Scholar | Crossref | Medline | ISI10. Habib, A, Khatun, S. Krukenberg tumor: report of two cases. Mymensingh Med J 2012; 21: 348–352.
Google Scholar | Medline11. Niwa, K, Yoshimi, N, Sugie, S, et al. A case of double cancer (pancreatic and ovarian adenocarcinomas) diagnosed by exfoliative and fine needle aspiration cytology. Jpn J Clin Oncol 1988; 18: 167–173.
Google Scholar | Medline12. Nomoto, D, Hashimoto, D, Motohara, T, et al. Hepatobiliary and pancreatic: rapid growing cystic ovarian metastasis from pancreatic cancer. J Gastroenterol Hepatol 2016; 31: 707.
Google Scholar | Crossref | Medline13. Hart, WR. Diagnostic challenge of secondary (metastatic) ovarian tumors simulating primary endometrioid and mucinous neoplasms. Pathol Int 2005; 55: 231–243.
Google Scholar | Crossref | Medline14. Meriden, Z, Yemelyanova, AV, Vang, R, et al. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol 2011; 35: 276–288.
Google Scholar | Crossref | Medline15. Yazigi, R, Sandstad, J. Ovarian involvement in extragenital cancer. Gynecol Oncol 1989; 34: 84–87.
Google Scholar | Crossref | Medline16. Lowery, M, Klimstra, D, Hedvat, C, et al. A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of Kras mutation molecular phenotyping to demonstrate independent primary origin. Gastrointest Cancer Res 2012; 5: 67–70.
Google Scholar | Medline17. Bamford, S, Dawson, E, Forbes, S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355–358.
Google Scholar | Crossref | Medline | ISI18. Ayhan, A, Guvenal, T, Salman, MC, et al. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol 2005; 98: 235–241.
Google Scholar | Crossref | Medline19. Golan, T, Hammel, P, Reni, M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381: 317–327.
Google Scholar | Crossref | Medline20. Martino, C, Pandya, D, Lee, R, et al. ATM-mutated pancreatic cancer: clinical and molecular response to gemcitabine/nab-paclitaxel after genome-based therapy resistance. Pancreas 2020; 49: 143–147.
Google Scholar | Crossref | Medline21. Goéré, D, Daveau, C, Elias, D, et al. The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol 2008; 34: 1335–1339.
Google Scholar | Crossref | Medline22. Brieau, B, Auzolle, C, Pozet, A, et al. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: a retrospective AGEO multicentre study. Dig Liver Dis 2016; 48: 441–445.
Google Scholar | Crossref | Medline23. Gunay, Y, Demiralay, E, Demirag, A. Pancreatic metastasis of high-grade papillary serous ovarian carcinoma mimicking primary pancreas cancer: a case report. Case Rep Med 2012; 2012: 943280.
Google Scholar | Crossref | Medline24. McCluggage, WG, Wilkinson, N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005; 47: 231–247.
Google Scholar | Crossref | Medline | ISI25. Prat, J. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol 2005; 18: S99–S111.
Google Scholar | Crossref | Medline26. Baker, PM, Oliva, E. Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int J Gynecol Pathol 2005; 24: 39–55.
Google Scholar | Medline27. Goldstein, NS, Bassi, D, Uzieblo, A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001; 116: 246–252.
Google Scholar | Crossref | Medline28. Vang, R, Gown, AM, Barry, TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol 2006; 19: 97–105.
Google Scholar | Crossref | Medline | ISI29. Lee, KR, Young, RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol 2003; 27: 281–292.
Google Scholar | Crossref | Medline | ISI30. Auner, V, Kriegshäuser, G, Tong, D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009; 9: 111.
Google Scholar | Crossref | Medline31. Iacobuzio-Donahue, CA, Fu, B, Yachida, S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806–1813.
Google Scholar | Crossref | Medline | ISI32. Grünewald, K, Lyons, J, Fröhlich, A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989; 43: 1037–1041.
Google Scholar | Crossref | Medline | ISI33. Bournet, B, Muscari, F, Buscail, C, et al. KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol 2016; 7: e157.
Google Scholar | Crossref | Medline